



July 24, 2025

The provider bulletins and/or frequently asked questions (FAQs) summarized below include hyperlinks ([Learn more>>](#)) to full versions. Should you ever experience an issue with any of the hyperlinks, you may access all provider bulletins and FAQs at [FloridaBlue.com > for providers > news > bulletins-and-faqs](https://www.floridablue.com/for-providers/news/bulletins-and-faqs).

For Florida Blue and Truli for Health Providers

ADMINISTRATIVE NEWS

Reminder to Verify Your Information to Remain in Our Provider Directories

Federal law requires all providers, health care facilities, and suppliers to verify and update their profile information with payers each quarter – even if their information has not changed. If your information is not updated timely, it will be removed from our directories, as required by law. It will be added back to the provider directory once the required information is received. [Learn more>>](#)

NATURAL DISASTERS/HURRICANES

Remember These Important Guidelines During Hurricane Season

Natural disasters and other emergencies are unpredictable; however, we can be prepared and understand how to complete required transactions if a disaster occurs. Please remember to accept member ID cards from Florida Blue and Truli for Health members. We are providing other important reminders and guidelines to follow during these types of events. [Learn more>>](#)

PHARMACY

Pharmacy Updates to Commercially Insured Medical Coverage Guidelines Now Available

Each month and quarter, our Medical Coverage Guidelines (MCG) for the commercially insured are updated and published at [FloridaBlue.com](https://www.floridablue.com) under *Medical and Pharmacy Policies and Guidelines, What's New*. The July 15, 2025 updates include, but are not limited to, an update to the **Erythropoiesis stimulating agents** MCG to include Epogen as a preferred agent along with Procrit and Retacrit. MCG for **Amyvuttra, Attriby, Onpattro, Vyndamax, Vyndaqel, and Wainua** have also been updated to reflect preferred products for cardiomyopathy of transthyretin-mediated amyloidosis (ATTR-CM) or polyneuropathy of transthyretin-mediated amyloidosis (ATTR-PN). The preferred

products include Attruby, Vyndamax, Vyndaqel, and Wainua. Forthcoming changes to antiemetics on October 1, 2025 will include the addition of Focinvez (J1434) and Posfrea (J2468) to prior authorization. Many other MCG updates are listed. [Learn more>>](#)

PROVIDER SELF-SERVICE TOOLS

Availity Essentials Update: Enhancing Authorization Submissions for Inpatient Services

We are streamlining the authorization submissions process for inpatient services in Availity Essentials by clarifying requirements for procedure codes. These changes should also reduce errors and inconsistencies in procedure code submissions. [Learn more>>](#)

For Florida Blue Providers Only

QUALITY / HEDIS / CAHPS

Keep Your Patients Healthy Through HPV Vaccination for the New School Year

Health care providers play an essential role in increasing human papillomavirus (HPV) vaccine rates among patients, particularly pre-adolescents ages 9 to 13. A physician's recommendation is key in motivating parents to have their children vaccinated against HPV. Be sure to make the HPV vaccine a priority before the new school year begins.

[Learn more>>](#)

Register to Attend Florida Blue's Next HEDIS Innovations Webinar on July 29

Join us for our next webinar on July 29, 2025. You will hear best practices and the latest on the Adult Immunization Status (AIS) and Childhood Immunization Status (CIS), as well as other preventive HEDIS measures. Continuing medical education (CME) credit is available. [Learn more>>](#)

Statins for Patients with Diabetes and Cardiovascular Disease

Many of our adult members, your patients, are living with diabetes and/or heart disease. Together, we can help improve their health by following HEDIS quality guidelines from the Statins for Patients with Diabetes and Cardiovascular Disease measure. [Learn](#)

[more>>](#)

UTILIZATION MANAGEMENT AND OTHER PROGRAMS

Change in Medicare Post Acute Care Program Management

Effective October 1, 2025, management of our Medicare Post Acute Care (PAC) program will transition from CareCentrix to Florida Blue Utilization Management. The PAC program will continue to provide authorizations for post-acute placement at skilled nursing facilities, acute inpatient rehabilitation, subacute rehabilitation, and long-term acute care. [Learn more>>](#)